{"id":"cosyntropin","rwe":[],"_fda":{"id":"094426f5-3a15-37e5-e063-6394a90aa985","set_id":"09441f78-7350-0cb3-e063-6394a90a46ab","openfda":{"nui":["M0000499","N0000175941"],"unii":["72YY86EA29"],"route":["INTRAVENOUS"],"spl_id":["094426f5-3a15-37e5-e063-6394a90aa985"],"brand_name":["Cosyntropin"],"spl_set_id":["09441f78-7350-0cb3-e063-6394a90a46ab"],"package_ndc":["71872-7313-1"],"product_ndc":["71872-7313"],"generic_name":["COSYNTROPIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Adrenocorticotropic Hormone [CS]"],"substance_name":["COSYNTROPIN"],"pharm_class_epc":["Adrenocorticotropic Hormone [EPC]"],"manufacturer_name":["Medical Purchasing Solutions, LLC"],"application_number":["ANDA202147"],"original_packager_product_ndc":["0781-3440"]},"version":"1","pregnancy":["Pregnancy Pregnancy Category C. Animal reproduction studies have not been conducted with Cosyntropin for Injection. It is also not known whether Cosyntropin for Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cosyntropin for Injection should be given to a pregnant woman only if clearly needed."],"references":["REFERENCES 1. Wood, J.B. et al. LANCET 1.243, 1965. 2. Greig, W.R. et al. J. ENDOCR 34.411, 1966. 3. McGill, P.E. et al. ANN RHEUM DIS 26.123, 1967. Manufactured by Oakwood Labs, Solon, Ohio for Sandoz Inc., Princeton, NJ Rev. July 2012"],"description":["DESCRIPTION Cosyntropin for Injection is a sterile lyophilized powder in vials containing 0.25 mg of Cosyntropin and 10 mg of mannitol to be reconstituted with 1 mL of 0.9% Sodium Chloride Injection, USP. Administration is by intravenous or intramuscular injection. Cosyntropin is a 1 to 24 corticotropin, a synthetic subunit of ACTH. It is an open chain polypeptide containing, from the N terminus, the first 24 of the 39 amino acids of natural ACTH. The sequence of amino acids in the 1 to 24 compounds is as follows: Image 1"],"precautions":["PRECAUTIONS General Cosyntropin for Injection exhibits slight immunologic activity, does not contain animal protein and is therefore less risky to use than natural ACTH. Patients known to be sensitized to natural ACTH with markedly positive skin tests will, with few exceptions, react negatively when tested intradermally with Cosyntropin for Injection. Most patients with a history of a previous hypersensitivity reaction to natural ACTH or a pre-existing allergic disease will tolerate Cosyntropin for Injection. Despite this however, Cosyntropin for Injection is not completely devoid of immunologic activity and hypersensitivity reactions including rare anaphylaxis are possible. Therefore, the physician should be prepared, prior to injection, to treat any possible acute hypersensitivity reaction. Drug Interactions Corticotropin may accentuate the electrolyte loss associated with diuretic therapy. Carcinogenesis, Mutagenesis, Impairment of Fertility Long term studies in animals have not been performed to evaluate carcinogenic or mutagenic potential or impairment of fertility. A study in rats noted inhibition of reproductive function like natural ACTH. Pregnancy Pregnancy Category C. Animal reproduction studies have not been conducted with Cosyntropin for Injection. It is also not known whether Cosyntropin for Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cosyntropin for Injection should be given to a pregnant woman only if clearly needed. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Cosyntropin for Injection is administered to a nursing woman. Pediatric Use (See DOSAGE AND ADMINISTRATION section.)"],"how_supplied":["HOW SUPPLIED Cosyntropin for Injection 0.25 mg is supplied as under: NDC # 0781-3440-95 Box of 10 vials Storage Store at 20° to 25°C (68° to 77°F); [See USP Controlled Room Temperature]. Excursions permitted to 15° to 30°C (59° to 86°F). Cosyntropin for Injection is lyophilized, single dose vial for diagnostic use only. It contains no antimicrobial preservative. Any unused portion should be discarded. Rx only"],"pediatric_use":["Pediatric Use (See DOSAGE AND ADMINISTRATION section.)"],"effective_time":"20231103","nursing_mothers":["Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Cosyntropin for Injection is administered to a nursing woman."],"adverse_reactions":["ADVERSE REACTIONS Since Cosyntropin for Injection is intended for diagnostic and not therapeutic use, adverse reactions other than a rare hypersensitivity reaction are not anticipated. A rare hypersensitivity reaction usually associated with a pre-existing allergic disease and/or a previous reaction to natural ACTH is possible. Symptoms may include slight whealing with splotchy erythema at the injection site. There have been rare reports of anaphylactic reaction. The following adverse reactions have been reported in patients after the administration of Cosyntropin for Injection and the association has been neither confirmed nor refuted: • bradycardia • tachycardia • hypertension • peripheral edema • rash"],"contraindications":["CONTRAINDICATION The only contraindication to Cosyntropin for Injection is a history of a previous adverse reaction to it."],"drug_interactions":["Drug Interactions Corticotropin may accentuate the electrolyte loss associated with diuretic therapy."],"general_precautions":["General Cosyntropin for Injection exhibits slight immunologic activity, does not contain animal protein and is therefore less risky to use than natural ACTH. Patients known to be sensitized to natural ACTH with markedly positive skin tests will, with few exceptions, react negatively when tested intradermally with Cosyntropin for Injection. Most patients with a history of a previous hypersensitivity reaction to natural ACTH or a pre-existing allergic disease will tolerate Cosyntropin for Injection. Despite this however, Cosyntropin for Injection is not completely devoid of immunologic activity and hypersensitivity reactions including rare anaphylaxis are possible. Therefore, the physician should be prepared, prior to injection, to treat any possible acute hypersensitivity reaction."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Cosyntropin for Injection exhibits the full corticosteroidogenic activity of natural ACTH. Various studies have shown that the biologic activity of ACTH resides in the N-terminal portion of the molecule and that the 1 to 20 amino acid residue is the minimal sequence retaining full activity. Partial or complete loss of activity is noted with progressive shortening of the chain beyond 20 amino acid residues. For example, the decrement from 20 to 19 results in a 70% loss of potency. The pharmacologic profile of Cosyntropin for Injection is similar to that of purified natural ACTH. It has been established that 0.25 mg of will stimulate the adrenal cortex maximally and to the same extent as 25 units of natural ACTH. This dose of Cosyntropin for Injection will produce maximal secretion of 17-OH corticosteroids, 17- ketosteroids and / or 17 - ketogenic steroids. The extra-adrenal effects which natural ACTH and Cosyntropin for Injection have in common include increased melanotropic activity, increased growth hormone secretion and an adipokinetic effect. These are considered to be without physiological or clinical significance. Animal, human and synthetic ACTH (1 to 39) which all contain 39 amino acids exhibit similar immunologic activity. This activity resides in the C-terminal portion of the molecule and the 22 to 39 amino acid residues exhibit the greatest degree of antigenicity. In contrast, synthetic polypeptides containing 1 to 19 or fewer amino acids have no detectable immunologic activity. Those containing 1 to 26, 1 to 24 or 1 to 23 amino acids have very little immunologic although full biologic activity. This property of Cosyntropin for Injection assumes added importance in view of the known antigenicity of natural ACTH."],"indications_and_usage":["INDICATIONS AND USAGE Cosyntropin for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see DOSAGE AND ADMINISTRATION section). Severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis. Many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed. For this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation. When presumptive adrenal insufficiency is diagnosed by a subnormal Cosyntropin for Injection test, further studies are indicated to determine if it is primary or secondary. Primary adrenal insufficiency (Addison's disease) is the result of an intrinsic disease process, such as tuberculosis within the gland. The production of adrenocortical hormones is deficient despite high ACTH levels (feedback mechanism). Secondary or relative insufficiency arises as the result of defective production of ACTH leading in turn to disuse atrophy of the adrenal cortex. It is commonly seen, for example, as result of corticosteroid therapy, Sheehan's syndrome and pituitary tumors or ablation. The differentiation of both types is based on the premise that a primarily defective gland cannot be stimulated by ACTH whereas a secondarily defective gland is potentially functional and will respond to adequate stimulation with ACTH. Patients selected for further study as the result of a subnormal Cosyntropin for Injection test should be given a 3 or 4 day course of treatment with Repository Corticotropin Injection USP and then retested. Suggested doses are 40 USP units twice daily for 4 days or 60 USP units twice daily for 3 days. Under these conditions little or no increase in plasma cortisol levels will be seen in Addison's disease whereas higher or even normal levels will be seen in cases with secondary adrenal insufficiency."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Cosyntropin for Injection may be administered intramuscularly or as a direct intravenous injection when used as a rapid screening test of adrenal function. It may also be given as an intravenous infusion over a 4 to 8 hour period to provide a greater stimulus to the adrenal glands. Doses of Cosyntropin for Injection 0.25 to 0.75 mg have been used in clinical studies and a maximal response noted with the smallest dose. A suggested method for a rapid screening test of adrenal function has been described by Wood and Associates (1). A control blood sample of 6 to 7 mL is collected in a heparinized tube. Reconstitute 0.25 mg of Cosyntropin for Injection with 1mL of 0.9% Sodium Chloride Injection, USP and inject intramuscularly. The reconstituted drug product should be inspected visually for particulate matter and discoloration prior to injection. Reconstituted Cosyntropin for Injection should not be retained. In the pediatric population, aged 2 years or less, a dose of 0.125 mg will often suffice. A second blood sample is collected exactly 30 minutes later. Both blood samples should be refrigerated until sent to the laboratory for determination of the plasma cortisol response by some appropriate method. If it is not possible to send them to the laboratory or perform the fluorimetric procedure within 12 hours, then the plasma should be separated and refrigerated or frozen according to need. Two alternative methods of administration are intravenous injection and infusion. Cosyntropin for Injection can be injected intravenously in 2 to 5 mL of saline over a 2-minute period. When given as an intravenous infusion: Cosyntropin for Injection, 0.25 mg may be added to glucose or saline solutions and given at the rate of approximately 40 micrograms per hour over a 6-hour period. It should not be added to blood or plasma as it is apt to be inactivated by enzymes. Adrenal response may be measured in the usual manner by determining urinary steroid excretion before and after treatment or by measuring plasma cortisol levels before and at the end of the infusion. The latter is preferable because the urinary steroid excretion does not always accurately reflect the adrenal or plasma cortisol response to ACTH. The usual normal response in most cases is an approximate doubling of the basal level, provided that the basal level does not exceed the normal range. Patients receiving cortisone, hydrocortisone or spironolactone should omit their pre-test doses on the day selected for testing. Patients taking inadvertent doses of cortisone or hydrocortisone on the test day and patients taking spironolactone or women taking drugs which contain estrogen may exhibit abnormally high basal plasma cortisol levels. A paradoxical response may be noted in the cortisone or hydrocortisone group as seen in a decrease in plasma cortisol values following a stimulating dose of Cosyntropin for Injection. In the spironolactone or estrogen group only a normal incremental response is to be expected. Many patients with normal adrenal function, however, do not respond to the expected degree so that the following criteria have been established to denote a normal response: The control plasma cortisol level should exceed 5 micrograms/100 mL. The 30-minute level should show an increment of at least 7 micrograms/100 mL above the basal level. The 30-minute level should exceed 18 micrograms/100 mL. Comparable figures have been reported by Greig and co-workers (2). Plasma cortisol levels usually peak about 45 to 60 minutes after an injection of Cosyntropin for Injection and some prefer the 60-minute interval for testing for this reason. While it is true that the 60-minute values are usually higher than the 30-minute values, the difference may not be significant enough in most cases to outweigh the disadvantage of a longer testing period. If the 60-minute test period is used, the criterion for a normal response is an approximate doubling of the basal plasma cortisol value. In patients with a raised plasma bilirubin or in patients where the plasma contains free hemoglobin, falsely high fluorescence measurements will result. The test may be performed at any time during the day but because of the physiological diurnal variation of plasma cortisol the criteria listed by Wood cannot apply. It has been shown that basal plasma cortisol levels and the post Cosyntropin for Injection increment exhibit diurnal changes. However, the 30-minute plasma cortisol level remains unchanged throughout the day so that only this single criterion should be used (3). Parenteral drug products should be inspected visually for particulate matter and discoloration whenever solution and container permit. Reconstituted Cosyntropin for Injection should not be retained."],"spl_product_data_elements":["Cosyntropin Cosyntropin MANNITOL COSYNTROPIN COSYNTROPIN"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL Cosyntropin for Injection 0.25 mg/vial FOR DIAGNOSTIC USE ONLY Rx only For IV or IM Use Lyophilized and Must be diluted Discard unused portion 7313.jpg","PRINCIPAL DISPLAY PANEL - OUTER PACKAGE NDC 71872-7313-1 Rx Only Cosyntropin for Injection 0.25 mg 1 x 1mL Single-Dose Vial For IV or IM Use 7313.pdp"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Long term studies in animals have not been performed to evaluate carcinogenic or mutagenic potential or impairment of fertility. A study in rats noted inhibition of reproductive function like natural ACTH."]},"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"FOETAL GROWTH RESTRICTION","source":"FDA FAERS","actionTaken":"24 reports"},{"date":"","signal":"FOETAL EXPOSURE DURING PREGNANCY","source":"FDA FAERS","actionTaken":"23 reports"},{"date":"","signal":"HYPOGLYCAEMIA","source":"FDA FAERS","actionTaken":"20 reports"},{"date":"","signal":"HYPOTENSION","source":"FDA FAERS","actionTaken":"17 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"13 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"12 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"11 reports"},{"date":"","signal":"SEPSIS","source":"FDA FAERS","actionTaken":"11 reports"},{"date":"","signal":"ADRENAL INSUFFICIENCY","source":"FDA FAERS","actionTaken":"10 reports"},{"date":"","signal":"HYPERKALAEMIA","source":"FDA FAERS","actionTaken":"9 reports"}],"drugInteractions":[{"drug":"Diuretics","action":"Monitor","effect":"May accentuate electrolyte loss"}],"commonSideEffects":[{"effect":"Hypersensitivity reaction","drugRate":"rare","severity":"moderate"},{"effect":"Bradycardia","drugRate":"rare","severity":"moderate"},{"effect":"Tachycardia","drugRate":"rare","severity":"moderate"},{"effect":"Hypertension","drugRate":"rare","severity":"moderate"},{"effect":"Peripheral edema","drugRate":"rare","severity":"moderate"},{"effect":"Rash","drugRate":"rare","severity":"moderate"}],"contraindications":["History of a previous adverse reaction to Cosyntropin"],"specialPopulations":{"Pregnancy":"Data not available","Geriatric use":"Data not available","Paediatric use":"In pediatric patients aged 2 years or less, a dose of 0.125 mg is often sufficient.","Renal impairment":"Data not available","Hepatic impairment":"Data not available"},"seriousAdverseEvents":[{"event":"Anaphylactic reaction","detail":"","severity":"serious","incidence":"rare"}]},"trials":[],"_chembl":null,"aliases":["tetracosactide"],"patents":[{"type":"Data not available","filed":"Data not available","status":"Data not available","expires":"Data not available","territory":"Data not available","description":"Data not available","patentNumber":"Data not available"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=COSYNTROPIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:31:59.674048+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:32:05.171250+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:31:58.727986+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=COSYNTROPIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:32:05.523096+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:31:56.693921+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:31:56.693953+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:31:56.693959+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:32:07.071766+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Melanocortin receptor 2 agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:32:06.653723+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2103784/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:32:06.304402+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA202147","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:31:56.693963+00:00"}},"allNames":"COSYNTROPIN, cosyntropin, tetracosactide","offLabel":[],"timeline":[{"date":"Data not available","type":"neutral","milestone":"Discovery/IND filing","regulator":"none","description":"Initial development and IND filing for Cosyntropin."},{"date":"Data not available","type":"neutral","milestone":"Phase 1 initiation","regulator":"none","description":"Initiation of Phase 1 clinical trials."},{"date":"Data not available","type":"neutral","milestone":"Phase 2 initiation","regulator":"none","description":"Initiation of Phase 2 clinical trials."},{"date":"Data not available","type":"neutral","milestone":"Phase 3 initiation","regulator":"none","description":"Initiation of Phase 3 clinical trials."},{"date":"Data not available","type":"positive","milestone":"FDA approval for screening adrenocortical insufficiency","regulator":"FDA","description":"Approval by the FDA for use in screening adrenocortical insufficiency."}],"_dailymed":{"setId":"85d8da6c-744d-4b59-89b8-6908c6f2bb02","title":"COSACTHEN (COSYNTROPIN) INJECTION [DECHRA VETERINARY PRODUCTS, LLC]"},"aiSummary":"Cosyntropin is a synthetic ACTH analog used as a diagnostic agent to screen for adrenocortical insufficiency. It stimulates the adrenal cortex to assess cortisol response, aiding in the diagnosis of primary or secondary adrenal insufficiency. Approved by the FDA, Cosyntropin is a rapid and reliable tool for endocrinologists and clinicians. Its key advantage is the ability to perform a 30-minute test with minimal patient discomfort. While not a therapeutic agent, it plays a crucial role in diagnosing adrenal disorders, which can significantly impact patient management and outcomes.","ecosystem":[],"mechanism":{"target":"MC2 receptor","novelty":"me-too","modality":"peptide","drugClass":"Adrenocorticotropic Hormone [EPC]","explanation":"","oneSentence":"","technicalDetail":"Cosyntropin binds to melanocortin receptors on the adrenal cortex, specifically MC2 receptors, which are responsible for cortisol production. It has a short half-life and is rapidly metabolized, allowing for a quick and accurate assessment of adrenal function."},"_scrapedAt":"2026-03-27T23:32:15.651Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"notes":"","yoyGrowth":"","launchDate":"","marketShare":"","revenueYear":"","annualCostUS":"","currentRevenue":"","percentOfCompany":"","patientPopulation":"","peakSalesEstimate":"","genericCompetition":"no"},"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:32:09.546236+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"name":"Repository Corticotropin Injection","slug":"repository-corticotropin-injection","company":"Unknown","advantage":"Longer duration of action, used for more extensive adrenal function testing"}],"indications":{"approved":[{"line":"diagnostic","name":"Screening for adrenocortical insufficiency","notes":"","regulator":"FDA","approvalDate":""}],"offLabel":[{"name":"Post-dural puncture headache","notes":"Some studies suggest potential efficacy, but more research is needed.","evidenceLevel":"moderate"}],"pipeline":[{"name":"Post-dural puncture headache","notes":"","phase":"Phase 2","status":"terminated"},{"name":"Adrenal suppression","notes":"","phase":"Phase 2","status":"recruiting"},{"name":"Infantile spasms","notes":"","phase":"Phase 3","status":"suspended"}]},"labelChanges":[],"relatedDrugs":[{"name":"Adrenal Liquescence 3001","slug":"adrenal-liquescence","company":"Professional Complementary Health Formulas","genericName":"ADRENAL LIQUESCENCE","relationship":"same-class"},{"name":"GUNA-GERIATRICS","slug":"14-benzoquinone---arnica-montana---oxytocin---barium-carbonate---barium-oxalosuccinate---corticotropin---lead---levothyroxine---lutrelin---malic-acid---melatonin---neurotrophin-3---neurotrophin-4---phenylalanine---pork-liver---pyruvic-acid---rinfabate---sus-scrofa-adrenal-gland---sus-scrofa-frontal-lobe---sus-scrofa-hypothalamus---thyrotropin-alfa---brain-derived-neurotrophic-factor-human--","company":"Guna spa","genericName":"1,4-BENZOQUINONE - ARNICA MONTANA - OXYTOCIN - BARIUM CARBONATE - BARIUM OXALOSUCCINATE - CORTICOTROPIN - LEAD - LEVOTHYROXINE - LUTRELIN - MALIC ACID - MELATONIN - NEUROTROPHIN-3 - NEUROTROPHIN-4 - PHENYLALANINE - PORK LIVER - PYRUVIC ACID - RINFABATE - SUS SCROFA ADRENAL GLAND - SUS SCROFA FRONTAL LOBE - SUS SCROFA HYPOTHALAMUS - THYROTROPIN ALFA - BRAIN-DERIVED NEUROTROPHIC FACTOR HUMAN -","relationship":"same-class"},{"name":"Cortrosyn","slug":"cortrosyn","company":"Henry Schein, Inc.","genericName":"CORTROSYN","relationship":"same-class"},{"name":"XS H2O Liquescence","slug":"valeriana-officinalis-citricum-acidum-potassium-bitartrate-allium-sativum-arteria-suis-cerebrum-suis-kidney-(suis)-rauwolfia-serpentina-adrenocorticotrophin","company":"Nutritional Specialties, Inc.","genericName":"VALERIANA OFFICINALIS, CITRICUM ACIDUM, POTASSIUM BITARTRATE, ALLIUM SATIVUM, ARTERIA SUIS, CEREBRUM SUIS, KIDNEY (SUIS) RAUWOLFIA SERPENTINA, ADRENOCORTICOTROPHIN","relationship":"same-class"},{"name":"Household Dust and Mold Mix","slug":"glandula-suprarenalis-(bovine)-hepar-(bovine)-histaminum-hydrochloricum-alternaria-tenuis-nees-aspergillus-niger-candida-albicans-candida-parapsilosis-dust-mucor-racemosus-torula-cerevisiae-house-dust-mite-adrenocorticotrophin-rhizopus-nigricans","company":"Nutritional Specialties, Inc.","genericName":"GLANDULA SUPRARENALIS (BOVINE), HEPAR (BOVINE), HISTAMINUM HYDROCHLORICUM, ALTERNARIA TENUIS NEES, ASPERGILLUS NIGER, CANDIDA ALBICANS, CANDIDA PARAPSILOSIS, DUST, MUCOR RACEMOSUS, TORULA CEREVISIAE, HOUSE DUST MITE, ADRENOCORTICOTROPHIN, RHIZOPUS NIGRICANS","relationship":"same-class"},{"name":"911 Adrenal Burnout and Fatigue","slug":"aceticum-ac-adrenalinum-adrenocorticotrophin-(30x)-aesculus-hippocastanum-flos-alfalfa-alpha-lipoic-ac-ambra-arg-nit-avena-sativa-bryonia-carboneum-oxygenisatum-carpinus-betulus-flos-dna-fumaricum-acidum-gelsemium-sempervirens-hepar-sulphuris-calcareum-hypothalamus-kali-phosphoricum-lacticum-acidum-lecithin-natrum-muriaticum-oxalicum-acidum-phosphoricum-acidum-pituitarum-posterium-sarcolacticum-acidum-selenium-metallicum-sepia-silicea-succinicum-acidum-and-thyroidinum.","company":"King Bio Inc.","genericName":"ACETICUM AC, ADRENALINUM, ADRENOCORTICOTROPHIN (30X), AESCULUS HIPPOCASTANUM, FLOS, ALFALFA, ALPHA-LIPOIC AC, AMBRA, ARG NIT, AVENA SATIVA, BRYONIA, CARBONEUM OXYGENISATUM, CARPINUS BETULUS, FLOS, DNA, FUMARICUM ACIDUM, GELSEMIUM SEMPERVIRENS, HEPAR SULPHURIS CALCAREUM, HYPOTHALAMUS, KALI PHOSPHORICUM, LACTICUM ACIDUM, LECITHIN, NATRUM MURIATICUM, OXALICUM ACIDUM, PHOSPHORICUM ACIDUM, PITUITARUM POSTERIUM, SARCOLACTICUM ACIDUM, SELENIUM METALLICUM, SEPIA, SILICEA, SUCCINICUM ACIDUM AND THYROIDINUM.","relationship":"same-class"},{"name":"Chemstat","slug":"glycerinum-taraxacum-officinale-phytolacca-decandra-arsenicum-album-nitricum-acidum-nux-vomica-petroleum-phosphoricum-acidum-phosphorus-acetylsalicylicum-acidum-glonoinum-insulinum-(human)-lithium-carbonicum-thyroidinum-(suis)-aceticum-acidum-benzoicum-acidum-benzyl-alcohol-boricum-acidum-chlorinum-cortisone-aceticum-eugenol-folliculinum-isopropyl-palmitate-lacticum-acidum-petroleum-jelly-phenyl-butazone-plumbum-metallicum-potassium-sorbate-resorcinum-salicylicum-acidum","company":"Energique, Inc.","genericName":"GLYCERINUM, TARAXACUM OFFICINALE, PHYTOLACCA DECANDRA, ARSENICUM ALBUM, NITRICUM ACIDUM, NUX VOMICA, PETROLEUM, PHOSPHORICUM ACIDUM, PHOSPHORUS, ACETYLSALICYLICUM ACIDUM, GLONOINUM, INSULINUM (HUMAN), LITHIUM CARBONICUM, THYROIDINUM (SUIS), ACETICUM ACIDUM, BENZOICUM ACIDUM, BENZYL ALCOHOL, BORICUM ACIDUM, CHLORINUM, CORTISONE ACETICUM, EUGENOL, FOLLICULINUM, ISOPROPYL PALMITATE, LACTICUM ACIDUM, PETROLEUM JELLY, PHENYL BUTAZONE, PLUMBUM METALLICUM, POTASSIUM SORBATE, RESORCINUM, SALICYLICUM ACIDUM,","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05149638","phase":"NA","title":"Updated Diagnostic Cortisol Values for Adrenal Insufficiency","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2022-02-03","conditions":"Adrenal Insufficiency","enrollment":90},{"nctId":"NCT04546126","phase":"EARLY_PHASE1","title":"Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)","status":"RECRUITING","sponsor":"Benjamin Viglianti","startDate":"2021-11-01","conditions":"Radiotracer, Hypertension, Cholesterol","enrollment":24},{"nctId":"NCT02339506","phase":"NA","title":"Stress and the Nervous System","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2015-04","conditions":"Autonomic Nervous System, Baroreflex, Stress, Physiological","enrollment":23},{"nctId":"NCT04037605","phase":"EARLY_PHASE1","title":"Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2020-02-09","conditions":"Sleep Restriction","enrollment":5},{"nctId":"NCT03142893","phase":"PHASE1","title":"Hormonal Mechanisms of Sleep Restriction - Axis Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter y. Liu","startDate":"2017-05-08","conditions":"Sleep Restriction","enrollment":80},{"nctId":"NCT02813655","phase":"PHASE2","title":"Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches (ESYBRECHE)","status":"TERMINATED","sponsor":"Hospices Civils de Lyon","startDate":"2016-10","conditions":"Post-dural Puncture Headache","enrollment":46},{"nctId":"NCT06190158","phase":"EARLY_PHASE1","title":"Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-05-15","conditions":"Type 2 Diabetes, Chronic Kidney Diseases","enrollment":125},{"nctId":"NCT04642391","phase":"","title":"Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2021-08-02","conditions":"Cirrhosis, Adrenal Insufficiency","enrollment":76},{"nctId":"NCT03514589","phase":"PHASE2","title":"NeSST2: The Development of a Noninvasive Short Synacthen Test","status":"RECRUITING","sponsor":"Sheffield Children's NHS Foundation Trust","startDate":"2012-10-12","conditions":"Adrenal Suppression","enrollment":12},{"nctId":"NCT02818660","phase":"NA","title":"Mass Spectrometry Based Cutoffs for Cortisol After Stimulation Tests","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2016-05-21","conditions":"Adrenal Insufficiency","enrollment":232},{"nctId":"NCT04461535","phase":"NA","title":"Corticotropin Stimulation in Adrenal Venous Sampling for Patients With Primary Aldosteronism(ADOPA)","status":"COMPLETED","sponsor":"Chongqing Medical University","startDate":"2020-07-08","conditions":"Primary Aldosteronism","enrollment":228},{"nctId":"NCT03793114","phase":"NA","title":"Screening and Stimulation Testing for Residual Secretion of Adrenal Steroid Hormones in Autoimmune Addison's Disease","status":"UNKNOWN","sponsor":"University of Bergen","startDate":"2018-09-26","conditions":"Primary Adrenal Insufficiency","enrollment":200},{"nctId":"NCT03905603","phase":"EARLY_PHASE1","title":"Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2019-10-08","conditions":"Polycystic Ovary Syndrome","enrollment":144},{"nctId":"NCT01421797","phase":"NA","title":"Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2006-10-10","conditions":"Hyperandrogenemia, Polycystic Ovary Syndrome, Obesity","enrollment":84},{"nctId":"NCT01764711","phase":"NA","title":"Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2013-01","conditions":"Postural Tachycardia Syndrome","enrollment":13},{"nctId":"NCT03368066","phase":"PHASE3","title":"Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2018-01-29","conditions":"Adrenal Insufficiency, Cirrhosis, Spur Cell Anemia","enrollment":100},{"nctId":"NCT03347526","phase":"PHASE3","title":"A Novel Approach to Infantile Spasms","status":"SUSPENDED","sponsor":"University of Colorado, Denver","startDate":"2018-04-19","conditions":"Infantile Spasm","enrollment":394},{"nctId":"NCT03400852","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy","status":"TERMINATED","sponsor":"Mallinckrodt ARD LLC","startDate":"2018-07-27","conditions":"Muscular Dystrophy, Duchenne","enrollment":44},{"nctId":"NCT00851942","phase":"PHASE4","title":"Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test","status":"COMPLETED","sponsor":"Cardiff University","startDate":"2008-09","conditions":"Healthy, Adrenal Insufficiency, Hypopituitarism","enrollment":165},{"nctId":"NCT01062568","phase":"PHASE3","title":"The Adrenal Contribution to Androgen Production in Girls During Puberty","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2010-02","conditions":"Development","enrollment":50},{"nctId":"NCT03752190","phase":"PHASE4","title":"Comparison of Intramuscular and Intravenous ACTH Stimulation Test in Normal Volunteers","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2019-07","conditions":"Adrenal Insufficiency","enrollment":""},{"nctId":"NCT03709381","phase":"EARLY_PHASE1","title":"Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2017-10-01","conditions":"Adrenal Insufficiency, Osteopenia, Osteoporosis, Steroid Suppression of ACTH Secretion","enrollment":10},{"nctId":"NCT03083834","phase":"NA","title":"Salivary Free Cortisol Response to Cosyntropin Stimulation Test in Mitotane Treated Patients","status":"UNKNOWN","sponsor":"Bnai Zion Medical Center","startDate":"2017-03-14","conditions":"Adrenal Insufficiency, Adrenal Cancer","enrollment":50},{"nctId":"NCT03074123","phase":"NA","title":"Cortisol Response to Low Dose Cosyntropin Stimulation Test in the Late Afternoon","status":"COMPLETED","sponsor":"Bnai Zion Medical Center","startDate":"2017-04-01","conditions":"Adrenal Insufficiency","enrollment":20},{"nctId":"NCT01422707","phase":"EARLY_PHASE1","title":"Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess","status":"WITHDRAWN","sponsor":"University of Virginia","startDate":"2018-01-19","conditions":"Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome","enrollment":""},{"nctId":"NCT01422096","phase":"EARLY_PHASE1","title":"Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess","status":"WITHDRAWN","sponsor":"University of Virginia","startDate":"2018-06-01","conditions":"Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome","enrollment":""},{"nctId":"NCT01422733","phase":"EARLY_PHASE1","title":"Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction","status":"WITHDRAWN","sponsor":"University of Virginia","startDate":"2018-06-01","conditions":"Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome","enrollment":""},{"nctId":"NCT00989781","phase":"NA","title":"Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2009-09","conditions":"Polycystic Ovary Syndrome","enrollment":41},{"nctId":"NCT01673087","phase":"PHASE1","title":"Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2012-10","conditions":"Stress","enrollment":256},{"nctId":"NCT02368379","phase":"NA","title":"Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2014-03","conditions":"Prader Willi Syndrome, Adrenal Insufficiency","enrollment":23},{"nctId":"NCT01428336","phase":"NA","title":"Value of 25 mcg Cortrosyn Stimulation Test","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2011-09","conditions":"Adrenal Insufficiency","enrollment":22},{"nctId":"NCT02394457","phase":"PHASE4","title":"Cosyntropin Versus Epidural Blood Patch (EBP) for Treatment of Treatment of Post Dural Puncture Headache","status":"COMPLETED","sponsor":"United States Naval Medical Center, San Diego","startDate":"2010-08","conditions":"Postdural Puncture Headache","enrollment":29},{"nctId":"NCT00542841","phase":"NA","title":"Examining Genetic Differences Among People With 21-Hydroxylase Deficiency","status":"COMPLETED","sponsor":"Maria I. New","startDate":"2007-08","conditions":"21-hydroxylase Deficiency","enrollment":99},{"nctId":"NCT01839812","phase":"PHASE1","title":"Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2009-03","conditions":"Adrenal Cortex Diseases, Infant Morbidity","enrollment":35},{"nctId":"NCT01371526","phase":"PHASE4","title":"Revival of Stem Cells in Addison's Study","status":"COMPLETED","sponsor":"Newcastle University","startDate":"2010-09","conditions":"Adrenal Failure","enrollment":13},{"nctId":"NCT00694863","phase":"PHASE2","title":"Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2008-07","conditions":"Idiopathic Membranous Nephropathy","enrollment":20},{"nctId":"NCT00744588","phase":"","title":"Stress, Hypothalamic-pituitary-adrenal (HPA) Dysfunction, and Relapse in Alcoholism","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-08","conditions":"Alcohol Dependence","enrollment":75},{"nctId":"NCT00975078","phase":"PHASE4","title":"Test Predicting Adrenal Insufficiency in Volunteers Under Prednisone Treatment","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2009-05","conditions":"Adrenal Gland Hypofunction","enrollment":39},{"nctId":"NCT00415701","phase":"PHASE4","title":"Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2006-11","conditions":"Coronary Artery Disease, Mitral Valve Regurgitation","enrollment":130},{"nctId":"NCT00598377","phase":"NA","title":"Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2006-09","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":49},{"nctId":"NCT00006270","phase":"","title":"Study of the Approximate Entropy of Adrenocorticotropic Hormone and Cortisol Secretion in Patients With Head Injury","status":"UNKNOWN","sponsor":"National Center for Research Resources (NCRR)","startDate":"1998-02","conditions":"Brain Injury, Craniocerebral Trauma","enrollment":32}],"_emaApprovals":[],"_faersSignals":[{"count":24,"reaction":"FOETAL GROWTH RESTRICTION"},{"count":23,"reaction":"FOETAL EXPOSURE DURING PREGNANCY"},{"count":18,"reaction":"HYPOGLYCAEMIA"},{"count":15,"reaction":"DYSPNOEA"},{"count":12,"reaction":"HYPOTENSION"},{"count":12,"reaction":"NAUSEA"},{"count":11,"reaction":"HYPERKALAEMIA"},{"count":11,"reaction":"PNEUMONIA"},{"count":10,"reaction":"OFF LABEL USE"},{"count":10,"reaction":"RASH"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"💉","route":"Intravenous","frequency":"single dose","formulation":"injection"},"crossReferences":{"chemblId":"CHEMBL2103784"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[{"notes":"","period":"Data not available","companyName":"Unknown","relationship":"Originator"}],"publicationCount":656,"therapeuticAreas":["Metabolic"],"trialPhaseCounts":{"":3,"NA":14,"PHASE1":3,"PHASE2":4,"PHASE3":3,"PHASE4":6,"EARLY_PHASE1":8},"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"COSYNTROPIN","genericName":"COSYNTROPIN","companyName":"","companyId":"","modality":"Recombinant protein","firstApprovalDate":"1970","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1987-02-10T00:00:00.000Z","mah":"AMPHASTAR PHARMS INC","brand_name_local":null,"application_number":"NDA016750"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-11-27T00:00:00.000Z","mah":"SANDOZ","brand_name_local":null,"application_number":"ANDA202147"},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:32:09.546236+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}